|
Bedford Laboratories Begins Shipping Irinotecan HCl Injection
Bedford, OH - January 29, 2009 - Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., begins shipping Irinotecan HCl Injection. This product is AP rated and equivalent to Camptosar® by Pfizer. Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following intial fluorouracil-based therapy. "In our continuing effort to offer the most comprehensive and cost effective line of oncology and oncology adjunct products in the multisource industry, Bedford Laboratories is once again very pleased to offer this very important product," said David Gaugh, Vice President of Bedford Laboratories. Bedford Laboratories will supply Irinotecan HCl Injection as a sterile aqueous solution available in two different dosages including 40mg / 2mL single dose amber vials indivually boxed and 100mg / 5 mL single dose amber vials individually boxed. Prescribing information is available upon request from the Bedford Laboratories' professional services department at 1-800-521-5169. Camptosar® is a registered trademark of Pfizer Inc. |
